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A b s t r a c t  
In the present study, an attempt was made to develop immediate-release enteric-coated time 
release tablets of salbutamol sulphate for the treatment of nocturnal asthma. Nocturnal asthma is an 
asthma phenotype marked by nighttime increases in airway inflammation, airway hyper 
responsiveness, and expiratory airflow limitation. The occurrence of nocturnal asthma is associated 
with increased morbidity and inadequate asthma control, and has an important negative impact on 
quality of life. Formulation of enteric-coated time release tablets with suitable lag time could address 
the problems associated with asthma. To achieve this goal, immediate release tablets were 
prepared by direct compression method using superdisintegrants that contribute to the faster 
disintegration of tablet and thereby improved solubility of the drug. Different disintegrants like cross 
caramellose sodium, crospovidone and sodium starch glycolate in different concentrations (2.5 ă 
7.5%w/w) were tried in order to further improve disintegration time. The formulation, which showed 
best disintegration and dissolution profile, was coated with ethyl cellulose as inner layer and 
Eudragit S100 as outer enteric-coating polymer which does not dissolve at gastric pH but dissolve at 
intestinal pH, releasing the drug immediately in the alkaline medium. The optimized enteric-coated 
formulation E6 containing 2.5%w/w of Eudragit S 100 and 30%w/w of ethyl cellulose as coating 
system inhibited the release of the drug in 0.1 N HCl,  and whereas 99.04% of drug was released in 
the intestinal medium. Thus, dissolution profiles indicated that E6 tablet may be better alternative in 
the treatment of nocturnal asthma which overcomes the problems of conventional forms. 
Keywords: salbutamol sulphate, ethyl cellulose, pH sensitive polymer, time release, lag time.  
Introduction 
For centuries, the biological rhythms of the human body and their 
association to conventional environmental cycles have been 
studied. It has been reproved by ancient healers that, to be 
successful, treatment had to be offered with regard for various 
external and internal cycles. A biological rhythm is a self-sustaining 
process inside the human body. It is defined as the processes that 
occur periodically in an organism in conjunction with and often in 
response to periodic changes in environmental condition [1]. 
Biological rhythm within a single day is termed as circadian rhythm. 
Here, the oscillation time is 24 hours. Term Circadian is derived 
from the Latin term circa meaning „about" and dies which is 
derived from "a day" [2]. Also, each term indicates an oscillation 
period of time. The concept of  chronotherapeutics is utilized and 
devoted to the design and evaluation of drug delivery systems that 
release a therapeutic agent  at a rhythm that ideally matches the 
biological requirements of a given disease therapy. Disease 
conditions where constant drug levels are not preferred but need a 
pulse of therapeutic concentration in a periodic manner acts as a 
push for the development of time drug delivery systems. These 
systems have a peculiar mechanism of delivering drug rapidly and 
completely after a „lag time‰ i.e. a period of no drug release, 
characterized by a programmed drug release [3]. Asthma is one of 
the most common ailments with the largest circadian variation [4]. It 
is a disease of lung airways (bronchi) characterized by hyper-
responsiveness to a variety of stimuli [5, 6].  Nocturnal asthma is 
defined as a variable night time exacerbation of the underlying 
asthma condition associated with increased airway responsiveness 
and worsening of lung functions [7]. The lung function (peak 
expiratory flow rate, FEV1) is usually highest at 4 pm and lowest at 
4 am. Generally, asthma attacks are more prevalent in early 
morning [8]. It is inconvenient for a patient to take medicine at 
midnight. In this condition, a drug delivery system that can release 
the drug at a predetermined time to guarantee therapeutic efficacy 
is a prerequisite. With the advancement of technology in the 
pharmaceutical field, drug delivery systems that synchronize the 
drug delivery with the circadian variation in periods of increased 
risk are highly desirable for management of asthma. Ideal oral 
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timed drug delivery systems would overcome the problem of 
administering the drugs frequently. 
A time delayed release profile is characterized by a lag time 
followed by rapid and complete drug release [9].Several 
approaches to delay drug release exists. The application of an 
enteric coating to a solid dosage form is a well established 
approach to prevent drug release in the stomach and allow release 
in the small intestine. The most commonly used enteric coatings 
employ pH-dependent polymers which contain carboxylic groups. 
These remain un-ionized in the low pH environment of the 
stomach, and become ionized in the higher pH conditions of the 
small intestine, thus allowing the dissolution of the coating and 
drug is released in a controlled fashion from polymers. This allows 
time-controlled drug release when the symptoms of the disease are 
worse to fatal and ultimately this leads to improved patient 
compliance [10, 11]. Salbutamol sulphate is β2 receptor agonist 
widely used as bronchodilator to relieve acute as well as chronic 
attacks of asthma. Salbutamol sulphate dilates or enlarges the 
airways by relaxing the muscles surrounding the airways and 
thereby opens airways [12]. The objective of present study was to 
develop an enteric coated time release tablet based on 
chronopharmaceutical approach for the treatment of nocturnal 
asthma using salbutamol sulphate as a model drug.  
Materials and Methods 
Materials 
Salbutamol sulphate was a gift sample from S.M. Pharmaceuticals, 
Bengaluru. Eudragit S 100, Ethyl cellulose were obtained as gift 
samples from Gland Pharma Ltd., Mumbai. Acetones, Polyethylene 
glycol, Talc were procured from S. D. Fine chemicals Pvt. Ltd, 
Mumbai. Diethyl Pthalate was gifted from Pellet Pharma, 
Hyderabad. All other reagents used were of analytical grade. 
Methods 
Formulation of core tablet 
Core tablets containing 5 mg of salbutamol sulphate were prepared 
by direct compression method. Superdisintegrants such as cross 
caramellose sodium, crospovidone and sodium starch glycolate 
were used in varying concentrations (2.5 ă 7.5% w/w). The drug, 
diluents and superdisintegrants were passed through sieve no.40 
and mixed together in a plastic container. Magnesium stearate and 
aerosil passed through sieve no.80 were mixed and blended with 
above mixture. The mixed blend of excipients was compressed into 
tablets using 7 mm flat punches on a 10 stationed rotary 
compression machine. The core tablet formula is given in Table 1. 
 
 
Table 1: Formulae of core tablets  
Ingredients 
(mg) 
Formulation code                                           
 F1 F2 F3 F4 F5 F6 F7 F8 F9 
   Salbutamol sulphate  5 5 5 5 5 5 5 5 5 
   Cross caramellose sodium  5 10 15 --- --- --- --- --- --- 
   Crospovidone  --- --- --- 5 10 15 --- --- --- 
   Sodium starch glycolate  --- --- --- --- --- --- 5 10 15 
   Lactose  70 70 70 70 70 70 70 70 70 
   Microcrystalline cellulose  115 110 105 115 110 105 115 110 105 
  Magnesium stearate  3 3 3 3 3 3 3 3 3 
   Aerosil  2 2 2 2 2 2 2 2 2 
   Total weight (mg) 200 200 200 200 200 200 200 200 200 
 
Optimization of core tablets  
The core tablets were optimized based on the disintegration time 
and dissolution (in-vitro drug release studies) by using the different 
superdisintegrants in varying concentrations. The technical details 
and evaluation relating to core formulation are described in an 
earlier publication [13]. The optimised formulation F3 from the 
above batch of tablets was selected for present research work. 
Development of enteric coated time release tablets 
The optimised core tablet formulation F3 of salbutamol sulphate 
was first coated with ethyl cellulose (EC), a pH independent 
polymer as Inner hydrophobic layer and later it was coated with pH 
dependent polymer Eudragit S 100 (ES 100) as outer layer to 
protect the drug from disintegrating in stomach and to provide the 
necessary lag time essential for time delivery.  Different levels of 
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coating of Inner and outer layer for optimized immediate release 
formulation are shown in Table 2. The inner and outer polymer 
coats were applied by using conventional pan coating system. The 
conditions of coating operation are given in Table 3. A schematic 
diagram of the supposed enteric coated time release tablet is 
shown in Figure 1. 
 
 
     
Figure 1: Schematic diagram of enteric coated time release tablet 
 
Table 2: Different concentrations of inner and outer coating layers. 
 
Formulation Inner layer Outer layer
Ethyl cellulose% Eudragit S 100 %
 E1 5.0 2.5 
E2 10 2.5 
E3 15 2.5 
E4 20 2.5 
E5 25 2.5 
E6 30 2.5 
E7 35 2.5 
 
Table 3: Coating conditions for inner and outer polymeric layers. 
 
Apparatus  
conditions 
Inner layer Outer layer
Ethyl 
cellulose 
Eudragit S 
100  
Inlet temp (°C) 50-55 40-45
Exhaust temp (°C) 40-45 30-35
Spray rate (mL/min) 3-5 5
Spray gun distance from tablet 
bed 
10  ă  15 10  ă  15
Pan Speed(rpm) 25 25
 
Preparation of Ethyl cellulose inner coating solution and 
coating of core tablets 
The coating solution was prepared by hydrating EC in acetone by 
overnight storage. This hydrated solution was stirred for 15 mins. 
Plasticizer Diethylpthalate (% based on dry polymer weight) was 
added into the polymeric solution and mixed on a magnetic stirrer 
for another 10 mins. This polymer solution was then sprayed on to 
the core tablets in a conventional pan coating apparatus. The 
coating process was repeated till the desired levels of coatings 
were achieved. Seven different formulations were obtained by 
coating the tablets at different levels from 5 to 35%w/w (Table 2). 
The coated tablets were further dried in the coating pan for 15 mins 
[14].  
Preparation of Eudragit S 100 outer coating solution 
A homogeneous coating solution of pH sensitive polymer Eudragit 
S100 was prepared using PEG 400, talc and acetone. 1.25 % w/w 
PEG 400 was used as plasticizer (% based on dry polymer weight). 
Talc (2% of polymer weight) was used as a glidant and antitacking 
agent. The pH sensitive polymer Eudragit S100 was dissolved in 
acetone on magnetic stirrer, plasticizer was added and stirring 
continued till sufficient plasticization of the polymer was ensured, in 
order to get a good, intact and flexible polymeric film. Talc was 
then added and mixed till a homogenous mixture was obtained [15, 
16].  
Enteric/outer coating of ethyl cellulose coated core 
tablets  
Enteric coating of ethyl cellulose coated core tablets was 
performed by pan coating (Cipweka, India). Different ethyl cellulose 
coated formulations were coated with pH sensitive polymer 
Eudragit S100 at a coating level of 2.5% as total solid applied. 
Tablets were placed in the pan and coating solution was sprayed 
and dried with the help of inlet air. The coating process was 
repeated till the desired level of coating was achieved. The tablets 
were further dried in the coating pan for 15 mins. 
The % weight gain of enteric coated tablets was calculated using 
the following equation:   
 
% weight gain =    (Wt ă Wo)/Wo X 100 
 
Where Wt   is the weight of the tablet after coating, Wo is the initial 
weight of tablet [17].  
Evaluation of enteric coated time release tablets 
The prepared enteric coated time release tablets were evaluated 
for following properties:  
Film thickness 
The thickness of ten randomly selected tablets from each batch of 
coated tablets was individually recorded in mm using a vernier 
calliper. The mean and standard deviation values were calculated 
from each value recorded.  
Weight variation 
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The weight variation of the coated tablets was determined by 
official method as given in IP. The percentage difference in the 
weight variation for each batch of coated tablets was computed 
from average tablet weight of each batch. Ten tablets were used 
for weight variation test. 
Drug Content of enteric coated tablets 
10 tablets were weighed individually and powdered. Equivalent to 
one tablet of theoretical drug content was weighed and dispersed 
in 100 ml of pH 6.8 buffer. The UV absorbance was measured at 
276 nm against blank reagent. Test was performed in triplicate and 
drug content was calculated by using the following formula [18]. 
 
Drug content(mg) =(Absorbance Slope μ Intercept)X Dilution factor 
                                                                        1000 
Scanning electron microscopy (SEM) 
SEM has been extensively used to study the morphology and 
surface topography of the coated tablets [19]. The optimized 
enteric coated and uncoated tablets of salbutamol sulphate were 
tested for scanning electron microscopy to know the surface 
morphology and uniformity of thickness of the coating layer. The 
samples to be examined were mounted on the SEM sample stub 
using a double sided sticking tape. The samples mounted were 
coated with gold (200 A0) under reduced pressure (0.001 torr) for 5 
mins using an ion sputtering device. The gold coated samples were 
observed under the SEM and photomicrographs of suitable 
magnifications were obtained. 
Drug ă excipient compatibility studies by FT-IR 
Drug- excipient interactions play a crucial role with respect to the 
stability and potency of the drug. FT-IR technique was used to 
study the physical and chemical interaction between drug and 
excipients used.  The IR spectrum of pure drug, pure polymers 
ethyl cellulose, Eudragit S100 and Optimized enteric coated 
formulation were recorded in the stretching frequency range of 
400-4000 cm-1. The samples were prepared by KBr (Potassium 
Bromide) press pellet technique. 
Water uptake experiment  
The percentage of water uptake by the enteric coated tablets was 
determined in 100 ml of 0. 1 N HCl as medium filled in containers 
placed in horizontal shaker at 37ÀC. At predetermined time points 
the tablets were removed from the medium, carefully blotted with 
tissue paper to remove surface water, weighed and then placed 
back in the medium up to the time when the coating of the tablet 
started to rupture. Water uptake was calculated as amount of 
penetrated water related to dry tablet mass. 
 
% water uptake was calculated as follows: 
 
Water uptake (%) =(Wt ă Wo)/ Wo ïX 100 
 
Where Wt is weight of wet tablet at time t and Wo weight of dry 
tablet [20]. 
Lag time of enteric coated tablets (Rupture test)  
The time at which the outer coating layer starts to rupture is defined 
as the lag time. The intention of the study was to develop enteric 
coated tablets which remain protected from gastric environment 
and will release the drug rapidly in the intestine after administration. 
Providing suitable lag time for the enteric coated tablets would 
serve the purpose. Hence Lag time was determined, by placing the 
coated tablets in USP dissolution apparatus II containing  900 ml of 
0.1 N HCl for initial 2 hrs and then  changing to phosphate buffer of 
pH 6.8 till the coating ruptures. The media was agitated at 50 rpm 
and maintained at 37μ0.5°C. The time taken for outer coating to 
rupture was visually monitored and reported as lag time. In addition 
to the rupture behavior; the enteric coated tablets were 
photographed by a digital camera [21, 22]. 
Effect of inner layer concentration on lag time 
Core optimized tablet formula F3 was coated with different levels of 
ethyl cellulose as inner layer to obtain the required lag time. The 
core tablet F3 was coated with 5, 10, 15, 20, 25, 30 and 35%w/w of 
ethyl cellulose and obtained formulations were subjected to in vitro 
dissolution study.  Effect of ethyl cellulose layer concentration over 
lag time and release behavior was observed using a 
spectrophotometer, as described in the method under in vitro drug 
release studies.  
Disintegration time  
The disintegration test for the enteric coated tablets was carried out 
using USPXXIII (Electrolab, Bangalore, India) disintegration tester. 
Six enteric coated tablets were placed in each tube of the 
apparatus; the disintegration test was performed initially in pH 1.2 
without the discs for two hours. After 2 hrs, the same tablets were 
tested for disintegration in mixed pH 6.8 phosphate buffer as 
medium with the discs. The temperature of the water bath was 
maintained at 37 μ 5°C throughout the test. The disintegration time 
for the tablets was recorded in minutes [23].  
In-vitro dissolution studies 
Dissolution studies of the enteric coated tablets were carried out in 
triplicate employing USP type-II apparatus (USP XXIII Dissolution 
Test Apparatus) following conditions that simulate gastrointestinal 
tract. 0.1N HCl and phosphate buffer of pH 6.8 were used as 
dissolution medium. The temperature of the dissolution medium 
was maintained at 37μ0.5⁰C with a stirring speed of 50 rpm. 
Initially tablets were subjected to dissolution in 0.1N HCl for 2 hrs 
and after that media were changed to phosphate buffer pH 6.8. 
The samples were withdrawn at regular intervals of time and 
analysed for presence of drug by UV spectrophotometer at 276 
nm. The concentration of the drug was determined from standard 
calibration curve. The dissolution data was analysed for knowing 
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the amount of drug released and percentage cumulative drug 
released at different time intervals [23]. 
Drug release kinetics 
In order to study the mechanism of drug release from the prepared 
enteric coated time release tablets, the release data obtained was 
evaluated using zero-order release kinetics (Eq. 1), first order 
kinetics (Eq. 2), HiguchiÊs square root of time equation (Eq. 3) [24] 
and Korsemeyer and Peppas equation (Eq. 4) [25, 26].  
                                           Mt =M0 + k0t      (1) 
where Mt is the amount of drug dissolved in time t, M0 is the initial 
amount of drug in the solution, k0 is the zero-order release rate 
constant and t is the release time, 
                                          Mt = M0eăkt              (2) 
where Mt is the amount of drug dissolved in time t, M0 is the initial 
amount of drug in the solution, k is the first-order release rate 
constant and t is the release time, 
                                          Mt = kh “t           (3) 
Where Mt is the amount of drug dissolved in time t, kh is the 
Higuchi dissolution constant and t is the release time,  
                                          Mt/M¥ = kstn         (4) 
where, Mt and M¥ are the cumulative amount of drug released at 
time t and infinite time, respectively; ks 
is a constant incorporating structural and geometric characteristics 
of the device, and n is the drug release exponent, indicative of the 
mechanism of drug release. The values of n assigned to a cylinder 
are 0.45 for Fickian diffusion (case I) and 0.45 < n < 0.89 for non-
Fickian (anomalous) diffusion; and > 0.89 indicates super case II 
type of release respectively. Case II generally refers to the erosion 
of the polymeric chain and anomalous transport (non-Fickian) 
refers to a combination of both diffusion and erosion controlled-
drug release. 
Stability studies  
The stability studies were carried out for the optimized formulation 
at 40Ĉ°C/75% RH for a period of three months. The sample tablets 
were wrapped in the laminated aluminum foils and were placed in 
the accelerated stability chamber at 40°ĈC/75% RH for a period of 
three months. Sampling was done at a predetermined time 
intervals. The tablets were evaluated for their general appearance; 
drug content, lag time and in vitro drug release study [27].  
Results and Discussion 
The enteric coated time release tablet of salbutamol sulphate 
developed in the present study was a reservoir device where the 
tablet core was surrounded by two consecutive layers, a 
hydrophobic inner layer and an outer rupturable layer. Ethyl 
cellulose was coated as inner layer to avoid premature drug 
release in lower pH-media and to increase the lag time because of 
its reduced wettability, media uptake and erosion properties. 
Eudragit S 100 which hydrates and swells due to the presence of 
quaternary ammonium groups was selected as enteric coating 
polymer. Eudragit S 100 coating was given to the ethyl cellulose 
coated core tablets to achieve ideal time release tablets for 
treatment of nocturnal asthma. 
Optimization of core tablets  
The salbutamol sulphate timed release tablets consisted of inner 
core tablet containing drug reservoir and outer coating layer with 
various compositions to provide the suitable lag time. Various core 
tablets of salbutamol sulphate were prepared (F1-F9). The most 
important parameter that needs to be optimized in the development 
of core immediate release tablets is disintegration time of tablets. 
The disintegration time of the tablets prepared by using 
superdisintegrants was well within the limits. Cross caramellose 
sodium provided the immediate and highest release compared to 
other disintegrants. The In-vitro drug release profile of salbutamol 
sulphate immediate release tablets revealed that formulation F-3 
containing 15 mg of cross carmellose sodium (7.5% of tablet 
weight) released 98.58% of drug in 12 minutes in pH 6.8 
phosphate buffer and was considered as optimized formulation[13]. 
Hence for further research work, formulation F3 was utilised. 
Coating of core tablets  
Most of the time release systems contain a drug reservoir, 
surrounded by a barrier, which erodes/dissolves or ruptures. These 
barrier technologies used around the active agent are designed to 
degrade or dissolve after a certain time, and in those that the 
degradation of the polymer itself induces the release of the active 
agent. Ethyl cellulose, a pH independent polymer in different 
percentages from 5 to 35%w/w was applied as barrier coating 
between the core tablet and enteric coating using pan coating 
apparatus. This barrier avoids leaching of moisture into tablet core 
and erodes or dissolves after predetermined lag time.  Ethyl 
cellulose being hydrophobic does not interfere with tablet 
disintegration and provide the effective barrier from water to 
achieve the desired lag time required for the time release system. 
All the ethyl cellulose coated core tablets were pan coated with 
Eudragit S100 (2.5% w/w) to prevent the drug release in stomach. 
Eudragit S100 coating dissolves at pH ≥7 and complete release of 
drug occurs after a suitable lag time in the intestine.  The produced 
coated tablets had no visible defects such as orange peel effect, 
chipping, tacking or any other physical flaws. The coating system 
followed was dispersed in the minimum amount of time, and 
produced acceptable weight gains.   
Evaluation of enteric coated time release tablets 
Film thickness 
The mean thickness of the enteric coated tablets E1 to E7 was 
found to be 5.79, 5.93, 6.18, 6.33, 6.44, 6.53 and 6.65 mm 
respectively (Table 4). The thickness of the coated tablets 
increased with increase in the coat weight applied. The percentage 
increase in the thickness of tablets was found to be 2.8% - 18.1% 
for formulations E1- E7 respectively.  
Weight variation 
Sarfaraz et al. International Journal of Drug Delivery 6 (1) 64-74 [2014] 
 
PAGE | 69 |
 
 
The Weight variation results of enteric coated tablets are potrayed 
in Table 4. The average tablet weight for the coated tablets was in 
the range of 215.4 to 275 mg. The tablet weight variation was 
found below 2% for all the batches of coated tablets indicating it 
was within IP official limit. The percent practical weight gain 
calculated from the average tablet weight was found to be between 
7.7 to 37.5% for all batches of tablets respectively. 
Drug Content of enteric coated tablets 
The drug content of all the formulations was found to be with-in the 
official limits. The drug content was found in the range of 5.03 ă 
5.12 mg respectively (within the acceptable range) for all the 
formulations (Table 4). The results proved that coating process did 
not affect the integrity of tablet and no drug loss occurred during 
the coating process.  
 
Table 4: Characteristics of enteric coated time release tablets. 
 
      
     Formulation 
 
Thickness 
(mm)(MeanμSD, n=10) 
Weight variation (mg)
(MeanμSD, n=10) 
Drug Content (mg)(MeanμSD, 
n=3) 
 E1 5.79μ0.11 215.4μ1.40 5.05μ0.05 
E2 5.93μ0.01 224.6μ1.07 5.09μ0.03 
E3 6.18μ0.10 235.2μ0.91 5.04μ0.10 
E4 6.33μ0.20 245.3μ0.94 5.10μ0.13 
E5 6.44μ0.05 254.9μ0.99 5.03μ0.06 
E6 6.53μ0.01 265.0μ1.15 5.12μ0.11 
E7 6.65μ0.11 275.0μ0.81 5.10μ0.10 
 
Scanning electron microscopy 
The surface morphology of optimised coated tablet E6 and 
uncoated tablet as viewed by the scanning electron microscopy are 
shown in Fig. 2 (a) and (b) respectively. The SEM of uncoated 
tablet showed a rough, not very smooth surface with pores in it. 
The coated surface of E6 was fairly smooth and tight surface free 
from cracks or pores as visualized under high magnification. The 
surface view of the coated tablet revealed a distinct continuous and 
dense coat. 
 
 
 Figure 2: SEM Photomicrographs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) Surface morphology of uncoated tablet and                 b) Surface morphology of optimised enteric  coated time release tablet E6. 
 
Drug ă excipient compatibility studies by FT-IR 
The FT-IR spectra of optimised enteric coated time release tablet 
E6 is presented in Figure 3. The FT-IR spectra of coated tablets E6 
was compared with spectra of pure drug salbutamol sulphate to 
study the compatibility of drug and polymers or excipients used. 
The FT-IR spectrum of formulation E6 exihibited the characteristic 
absorption bands almost in the same pattern as that of pure drug 
 with 
prese
peak
 
 
Wat
Wate
E6 re
ruptu
ruptu
certa
depe
with 
linea
 
Figur
coate
 
Lag 
In th
sens
%
W
t
t
k
negligible differ
nt in the finger
s of pure drug 
er uptake exp
r uptake studies
vealed that wat
rable coating, 
re of outer coa
in lag time.  Th
ndent on outer 
slow increase 
rly (Figure 4).  
e 4: % Water up
d time release 
time of enter
e present stud
itive polymer Eu
Best fo
 3
   100
    95
    90
    85
    80
    75
    70
    65
%
Tr
an
sm
itt
an
ce
‐40
10
60
110
160
0
%
 W
at
er
 u
pt
ak
e
ence in the pos
 print region ar
in the same reg
Figure
eriment  
 performed for 
er influx was thr
which leads to
ting leads to r
e water uptake 
acrylate polyme
in water uptake
take and lag tim
tablet E6. 
ic coated tabl
y all the formu
dragit S 100 at
rmulation E
800  3600  3400
60 120
Lag Ti
S
ition of the ban
e totally in agre
ion.  These obs
 3: FT-IR spectr
optimised enter
ough the outer 
 erosion of in
apid release of 
capacity and dr
r coating. It was
 the lag time 
e studies of op
ets (Rupture 
lations were c
 2.5% w/w as o
2991
 3200  3000
180 240
me (mins)
arfaraz et al. 
ds. The peaks 
ement with the 
ervations ruled 
a of optimised e
ic coated tablet 
semipermeable 
ner layer. The 
the drug after 
ug release was 
 observed that 
also increased 
timized enteric 
test)  
oated with pH 
uter layer. The 
.801  0.112
 2800  2600
300
International 
 
out th
salbut
 
nteric coated tim
 
lag tim
not su
ruptur
with fo
releas
cellulo
Figure
conce
formu
140 to
which 
the dr
the ab
respec
ruptur
differe
 
 
 2400  2200 20
Wavenumber
Journal of Dr
e possibility of 
amol sulphate a
e release table
e or rupture st
fficient to conta
ed within 2 hrs 
rmulations E4 
e was noticed 
se layer in prov
 5.    It is evide
ntration was in
lations E5 ă E7 
 320 mins. Th
will be protecte
ug rapidly in the
ove batches s
t to their com
e behavior of 
nt time intervals
138
1189
1142.89
00  1800 1600
ug Delivery 6 
P
any chemical 
nd the other pol
t E6. 
udies indicated 
in the core tab
as seen with fo
ă E5 enhance
which solely ex
iding the lag tim
nt from the resu
creased the lag
provide more th
e aim of the st
d from gastric 
 intestine after 3
howed lag time
position coating
the enteric co
. 
6.774  29.629
1243
.970  55.214
4  140.279
1018.908  33.030
 1400  1200
(1) 64-74 [2
AGE | 70 |
interaction betw
ymer or excipien
that this level o
let and the tab
rmulations E1 ă
d lag time esse
plains the role 
e. The result i
lts that as the e
 time also enh
an two hours o
udy was to dev
environment an
-5 hours of adm
 in the require
 level. Figure 
ated time rele
.414  323.614
988.622  25.746
839.825
749.216  113
 1000   800
014] 
een the drug 
ts used. 
 
f coating was 
let eventually 
 E3. However 
ntial for time 
of inner ethyl 
s displayed in 
thyl cellulose 
anced.  The 
f lag time i.e., 
elop a tablet 
d will release 
inistration. So 
d range with 
6 depicts the 
ase tablet at 
  30.752
.094
  600
Sarfaraz et al. International Journal of Drug Delivery 6 (1) 64-74 [2014] 
 
PAGE | 71 |
 
 
Figure 5: Rupture test (Lag Time) of enteric coated time release tablets. 
 
                                     A (0 hrs)                                                           B (4.75 hrs)                                                C (5.25 hrs)            
  
Figure 6: Rupture sequence of enteric coated time release tablets. 
 
Effect of inner layer concentration on lag time 
Ethyl cellulose was coated as inner layer at different levels to 
achieve the required lag time. It was noticed that as the 
concentration of ethyl cellulose was increased from 5 ă 35%w/w 
the lag time also increased from 18 to 320 mins. Increase in coat 
thickness also caused resistance to water penetration and coat 
rupture.  As revealed in Fig. 5, with the increase of coat thickness, 
there was a corresponding increase in the lag time and subsequent 
drug release. Thus, percent coating mass gain was found to be 
another crucial parameter in the modulation of lag time and in 
achieving the desired drug release profile. A plot of percentage 
ethyl cellulose mass gain against lag time showed a good linear 
relationship, as shown in Fig. 7 (R2 = 0.908) indicating the vitality of 
this factor in lag time modulation. 
 
 
 
Figure 7: Plot of percent ethyl cellulose mass gain vs. lag time. 
 
Disintegration time  
The results of in-vitro disintegration studies are given in Table 5. It 
was observed that the formulations E1 ă E4 disintegrated in 0.1N 
HCl within 25 mins. The formulations failed the disintegration test in 
0.1 N HCl. This indicated that the amount of combination of inner 
ethyl cellulose (5 ă 20%w/w) and outer Eudragit S 100 polymer 
(2.5%w/w) layer in these formulations was unable to withstand acid 
media. Hence, three more formulations were prepared (E5 ă E7) 
with greater amount of inner ethyl cellulose coating material 
(weight gain up to 35%). Table 4 shows the increase in the ethyl 
cellulose coating (up to 35%w/w) resulted in non disintegration of 
the tablets in the acid media (0.1 N HCl) during the study period (2 
hrs). The observed results are in agreement with the reported 
literature showing the potential of this polymer combination to 
prevent disintegration in acidic media. The formulations E 5 ă E7 
disintegrated between 7 -15 mins when the test was done in mixed 
phosphate buffer pH 6.8. The results of these formulations 
indicated that disintegration time in pH 6.8 was found to increase 
with increase in percent weight gain by tablets. The data also 
suggested that the disintegration time was independent of the 
enteric coating weight gain but most likely depends on the inner 
polymer, in the current experimental condition. 
 
Table 5: Disintegration time of enteric coated time release tablets 
 
Formulation Disintegration Time in 
simulated gastric fluid 
(0.1 N HCl) 
Disintegration Time in 
simulated intestinal fluid 
(pH 6.8) 
E1 Disintegrated in 10 min -
E2 Disintegrated in12 min  -
E3 Disintegrated in 15 min  -
E4 Disintegrated in 25 min  -
E5 No Disintegration up to 
120 min 
07 min
E6 No Disintegration up to 
120 min 
13 min
E7 No Disintegration up to 
120 min 
15 min
 
In vitro Dissolution tests 
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In- vitro drug release studies was carried out for all the seven 
enteric coated time release formulations in simulated gastric 
environment (pH 1.2) for 2 hrs and then in simulated intestinal 
environment of pH 6.8. All formulations released the drug in the 
range of 84.50 to 99.04% in about 7.25 hrs. Formulations E1, E2, 
E3 and E4 released 98.60, 96.85, 93.48 and 91.77% of drug at the 
end of 4.25 hrs (Figure 8). In case of tablets E1- E4 it was evident 
from the nature of the graph that the outer Eudragit S 100 coating 
at 2.5%w/w and inner ethyl cellulose coating between 5 ă 20%w/w 
were unable to hold the core tablet from rupturing. This indicated 
that the lower level of coat polymer weight was insufficient to 
prevent the premature drug release. In fact the low coat thickness 
film formed around the core tablet retards drug release but 
diffusion of drug continues through such a film. The rapid release 
of drug in initial hours of dissolution study from these tablets 
suggested need for greater degree of mechanical strength of the 
coating. From these observations, it could be assumed that the first 
step in drug release was penetration of water in the core tablet by 
diffusion through Eudragit film and the rate and amount of water 
entered was dependent on film thickness. The penetration rate of 
water accelerated in to the core tablet due to outer polymer chain 
relaxation. When water reached the core tablet, a visible 
Âbreakdown, of the tablet matrix in to smaller granules was 
observed due to presence of superdisinterating agent 
croscarmellose sodium. The weakly held fragments of porous core 
tablet disaggregated into relatively fine particles under the rotating 
movement of the paddle. As a result the total water contact area 
with drug was enhanced and thereby maximum dissolution of drug 
was noticed. A cronomodulated release profile should be 
characterized by a lag time followed by rapid and complete drug 
release. After the desired lag time, the onset of release can be 
achieved by action of superdisintegrant in the core tablet. To 
achieve the above objective the formulations E5 ă E7 were 
designed by increasing the coating level of inner layer up to 
35%w/w. Formulations E5, E6 and E7 released 98.91, 99.04 and 
84.50% of drug in 7.5 hrs. The percent drug released versus time 
plot of these formulations revealed that they provided the needed 
lag time for chronomodulated delivery and also resisted the acidic 
medium up to 2 hrs. These plots also showed that the dissolution 
rate was inversely proportional to the thickness of the coat applied. 
As represented in Figure 5 the lag time for E5 ă E7 was 2.34, 4.80 
and 5.34 hrs respectively. The lag time increased with increase in 
inner ethyl cellulose coating level due to greater degree of 
mechanical strength of the thick coating which lowers rupturing. 
This made the outer acrylic coat more impermeable and drug 
release was retarded. The water uptake capacity and drug release 
before the rupture of tablet was dependent on outer acrylate 
polymer coating and inner ethyl cellulose layer (Figure 4). Slowly 
as the outer coating solubilized, drug dissolution through it was 
facilitated.  These findings were equally supported by disintegration 
studies of the enteric coated time release tablets. Furthermore, the 
pH of the dissolution medium played an important role in 
dissolution of coating in case of formulations E5 ă E7; increasing 
the pH of dissolution fluid accelerated the dissolution. Consistently 
faster drug release from coated tablet was observed in simulated 
intestinal dissolution fluid (pH 6.8) than acidic environment (pH 
1.2). The optimum coating level to obtain a suitable lag time and to 
initiate drug release at the target site (lower small intestine or 
lleocolon junction), was found with 2.5% (w/w) of Eudragit S 100 
and 30% (w/w) of ethyl cellulose polymeric film i.e., formulation E6.  
 
 
 
Figure 8: Cumulative percent of drug released versus time profile of enteric coated time release tablets 
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Drug release kinetics 
Values of the coefficient of determination for all the release models 
obtained for enteric coated time release tablets E1 ă E7 are given 
in Table 6. A comparative study of these values clearly showed 
that the Korsemeyer and Peppas model was the best-fit model for 
the batches prepared during the study except E6 and E7. The 
values of regression in the Korsemeyer and Peppas model (i.e., 
R2) were close to unit in all cases excluding E6 and E7. The n 
values were in the range of 0.06 ă 1.5 indicating super case II type 
of release. The drug release is attributed to the erosion of the outer 
Eudragit S100 film, which leads to the formation of pores that 
facilitate drug dissolution due to combination of both diffusion and 
erosion. The formulations E6 and E7 follow zero order release 
mechanism due to presence of higher quantity of polymer coat. 
 
Table 6: Comparative release model characteristics of enteric 
coated time release tablets 
Formulation Zero 
order 
First 
Order 
HiguchiÊs Korsemeyer 
and Peppas 
 E1 0.40 0.862 0.668 0.984 
E2 0.61 0.698 0.854 0.918 
E3 0.76 0.823 0.946 0.968 
E4 0.84 0.801 0.775 0.888 
E5 0.92 0.921 0.877 0.975 
E6 0.75 0.442 0.561 0.488 
E7 0.68 0.862 0.491 0.453 
 
Stability Studies  
The stability studies of optimum formulation E6 done at 40ĈC/75% 
RH revealed no change in physical appearance, no significant 
reduction in the drug content, lag time and drug release of the 
tablets occurred over a period of three months (Table 7).  
 
 
 
 
 
 
 
 
Table 7: Stability studies of enteric coated time release tablets at 
40ĈC/75% RH 
        
Formulation 
Drug content (mg) 
(MeanμSD, n=3) 
Lag Time 
(mins) 
%Cumulative 
drug   released 
E1 4.03μ0.01 16 96.40
E2 4.01μ0.04 28 94.05
E3 4.00μ0.01 30 90.02
E4 4.04μ0.10 90 88.24
E5 3.99μ0.04 130 95.12
E6 4.00μ0.08 275 96.02
E7 4.10μ0.02 304 80.30
 
Conclusion 
In accordance with chronotherapeutic model for nocturnal asthma, 
symptoms typically occur between midnight and especially around 
3 am to 6 am because of increased airway responsiveness and 
worsening of lung function. Thus in this study an attempt was made 
to design and evaluate a chronomodulated system of salbutamol 
sulphate, a bronchodilator for the treatment of asthma. To achieve 
this, salbutamol sulphate core tablets were coated with 
composition of hydrophobic inner ethyl cellulose and outer enteric 
Eudragit S-100 polymer. This coating composition i.e., 2.5w/w of 
Eudragit S-100 and 20 ă 35%w/w of ethyl cellulose helped achieve 
a definite non-release lag phase. The enteric coated time release 
tablets of salbutamol sulphate designed prevented drug release in 
stomach and released drug rapidly after predetermined lag time in 
the intestinal tract when pH was above 6. The intention was to 
administer the formulation at around 10.00 pm so that after a 
specified lag time the drug is rapidly available in the early morning 
hours to treat nocturnal asthma. The formulation E6 with 30%w/w 
coating of inner ethyl cellulose layer was considered optimized one 
as it provided 4.8 hrs of lagtime and 99.04% of drug release. Thus 
the above formulations are worth evaluating for chronotherapeutic 
treatment of nocturnal asthma. 
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